Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: TheBusDriver who wrote (13562)	7/19/2004 9:48:35 AM
From: Cal Gary	Read Replies (2) \| Respond to of 14101

Dimethaid Penecure phase I/II trial receives FDA OK 2004-07-19 09:12 ET - News Release Ms. Jodi Peake reports FDA APPROVES PENECURE ANTIFUNGAL TRIAL Dimethaid Research Inc. has received approval from the United States Food and Drug Administration for its an investigational new drug (IND) application for its antifungal treatment, Penecure. The approval covers the product's recently announced phase I/II trial as the first step in a full drug development plan also reviewed by the FDA. Penecure targets onychomycosis, a common nail fungus disease that affects up to 13 per cent of the population and represents a market estimated to be worth $1-billion in the United States. Although the seven-month, double-blinded, trial focuses on dose-ranging and safety, Dimethaid also expects to identify initial efficacy trends. "FDA involvement at this early stage is important," said Rebecca E. Keeler, president and chief executive officer. "It lends extra credibility to our clinical trial protocol and lays the groundwork for future clinical trials in the United States market." The first study will be conducted by four clinical investigators, all specialists in dermatology, at sites in Southern Ontario. The protocol calls for approximately 90 patients between the ages of 18 and 85, diagnosed with distal subungual onychomycosis in at least one greater toenail. Penecure takes advantage of Dimethaid's proprietary transcellular technology designed to minimize exposure to active drug and significantly lower the risk of side effects. The new product has already passed a proof-of-concept study at the University of California, as well as laboratory dose-ranging and accelerated stability studies. Unlike current antifungal lacquers, Penecure has demonstrated an ability to deliver clinically therapeutic levels of active drug through nails, directly targeting the disease site. PS Wayne, get well soon!! Best wishes.